Barclays analyst Carter Gould lowered the firm’s price target on Neurocrine to $160 from $180 and keeps an Overweight rating on the shares. Investor focus largely shifts back to the company’s commercial assets with NBI-1117568 skepticism unlikely to evolve favorably in near term and competitor overhangs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Election 2024: Where To Put Your Money Ahead of the Vote
- Biotech Alert: Searches spiking for these stocks today
- Tesla initiated, Foot Locker upgraded: Wall Street’s top analyst calls
- Neurocrine price target lowered to $136 from $143 at RBC Capital
- Neurocrine upgraded to Overweight from Neutral at Piper Sandler